Wu, Z., Wang, Z., Zhang, L., Song, X. (2025). Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.588